Intestinal Inflammation and Colorectal Cancer
Published on 1. November 2007
Book
Hardback
XV, 320 pages
978-1-4020-6825-6 (ISBN)
Description
This book is the proceedings of the Falk Symposium 158, on Intestinal Inflammation and Colorectal Cancer, held in March 2007. It covers the current understanding of inflammation-driven colon carcinogenesis, highlights the most relevant mechanisms and discusses measures to interfere with this process. This is a true translational topic which will attract both basic scientists and clinicians, specifically those who can make a difference in preventing this type of cancer.
Reviews / Votes
From the reviews:
"This book highlights the continuing research progress into the functional relationship between inflammation and the origin of intestinal cancer. . It highlights the most relevant mechanisms and possible preventive measures. The book ably encapsulates the current thinking in the field. This is aimed at both basic scientists and clinicians interested in this exciting and important translational topic that spans the interests of both those at the bench and those at the bedside. The contributing authors are all credible authorities in the field." (Willem JS de Villiers, MD, PhD, Doody's Review Service, March, 2008)
More details
Series
Edition
2007 ed.
Language
English
Place of publication
Dordrecht
Netherlands
Target group
Professional and scholarly
Professional/practitioner
Illustrations
XV, 320 p.
Dimensions
Height: 241 mm
Width: 160 mm
Thickness: 24 mm
Weight
676 gr
ISBN-13
978-1-4020-6825-6 (9781402068256)
DOI
10.1007/978-1-4020-6826-3
Schweitzer Classification
Content
Epidemiology of the villain.- Colorectal cancer in patients with inflammatory bowel disease: influence of nutritional habits and environmental clues.- Inflammatory bowel disease high-risk groups.- Not all colorectal cancers are the same.- Getting familiar with familial colon cancer.- The adenomatous polyposis coli tumour-suppressor protein in normal gut tissue maintenance and cancer.- Mismatch repair competency predicts 5-fluorouracil effectiveness on patient survival.- Inflammatory bowel disease-related cancer - just the same as sporadic? - Pro.- Differences between sporadic and colitis-associated colorectal cancer.- Screening and surveillance.- Endoscopic guidelines for hereditary non-polyposis colorectal cancer, familial adenomatous polyposis, inflammatory bowel disease and sporadic colorectal cancer.- Which new techniques will replace classical surveillance?.- How to deal with dysplasia and adenomatous polyps in inflammatory bowel disease.- Taking dysplasia to the molecular level.- Inflammation driven carcinogenesis: the players.- Cancer originating from bone marrow stem cells: can we extrapolate from gastritis to colitis?.- Translating laboratory findings into clinics: of mice and man.- How can we prevent?.- Inner and outer environment.- Can we prevent inflammatory bowel disease-related colorectal cancer with 5-aminosalicylic acid, azathioprine, or 6-mercaptopurine? The clinical evidence.- How can we prevent colorectal cancer with ursodeoxycholic acid?.- Molecular actions of 5-ASA - the magic bullet.- 5-Aminosalicylic acid and replication fidelity.- New mechanisms of action of 5-aminosalicylic acid: PPAR?: how it decreases inflammation and cancer.- Mesalazine and the prevention of colorectal cancer in inflammatory bowel disease.- Mesalazine and cell cycleprogression.- Chemopreventive role of mesalazine in inflammatory bowel disease-associated colorectal cancer: the role of DNA methylation.- Molecular actions of 5-aminosalicylic acid: the magic bullet on epidermal growth factor receptor signalling.- State-of-the-Art Lecture.- State-of-the-Art Lecture: Infection, inflammation and cancer - the future.- Progression of cancer through inflammatory mechanisms.- An integrating concept of malignant progression in colorectal cancer.- The balance between survival and apoptosis.- The tumour microenvironment regulates components of the fucose biosynthesis pathways in colorectal cancer cells.